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OBJECTIVE — Diabetes appears to increase risk for some cancers, but the association be-
tween preexisting diabetes and postoperative mortality in cancer patients is less clear. Our
objective was to systematically review postoperative mortality in cancer patients with and with-
out preexisting diabetes and summarize results using meta-analysis.
RSEARCH DESIGN AND METHODS — We searched the Medical Literature Analysis
and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE) for articles
published on or before 1 July 2009, including references of qualifying articles. We included
English language investigations of short-term postoperative mortality after initial cancer treat-
ment. Titles, abstracts, and articles were reviewed by at least two independent readers. Study
populationanddesign,results,andqualitycomponentswereabstractedwithstandardprotocols
by one reviewer and checked for accuracy by additional reviewers.
RESULTS — Of 8,828 titles identiﬁed in our original search, 20 articles met inclusion criteria
for qualitative systematic review. Of these, 15 reported sufﬁcient information to be combined in
meta-analysis.Preexistingdiabeteswasassociatedwithincreasedoddsofpostoperativemortality
across all cancer types (OR  1.85 [95% CI 1.40–2.45]). The risk associated with preexisting
diabeteswasattenuatedbutremainedsigniﬁcantwhenwerestrictedthemeta-analysistomodels
that controlled for confounders (1.51 [1.13–2.02]) or when we accounted for publication bias
using the trim and ﬁll method (1.52 [1.13–2.04]).
CONCLUSIONS — Compared with their nondiabetic counterparts, cancer patients with
preexisting diabetes are 50% more likely to die after surgery. Future research should investi-
gate physiologic pathways to mortality risk and determine whether improvements in perioper-
ative diabetes care can reduce postoperative mortality.
Diabetes Care 33:931–939, 2010
I
n established market economies, the
prevalence of diabetes in adults 20
yearsofagehasreachedalmost7%(1).
Because some cancers—including can-
cers of the breast, colorectum, endome-
trium, liver, and pancreas—occur more
commonly in individuals with diabetes,
the prevalence of diabetes in newly diag-
nosedcancerpatientsisevenhigher,with
estimates ranging 8–18% (2,3).
Among cancer patients, preexisting
diabetes is associated with a higher risk of
all-causelong-termmortality(4).Because
diabetes can lead to infections, metabolic
derangements, and acute cardiovascular
events, cancer patients with diabetes may
also be at greater risk of short-term mor-
tality, especially in the peri- and postop-
erative interval (2,5). However, this risk
has not been systematically studied. We
therefore sought to review and summa-
rize data evaluating the risk of short-term
postoperative mortality related to preex-
isting diabetes in newly diagnosed cancer
patients.
RESEARCH DESIGN AND
METHODS
Data sources and searches
We searched Medical Literature Analysis
and Retrieval System Online (MEDLINE)
andExcerptaMedicaDatabase(EMBASE)
from inception to 1 July 2009 for articles
evaluating the effect of diabetes on any
prognostic outcome in cancer patients.
Our overall search strategy included
terms for diabetes (e.g., diabetes, glucose
intolerance, hyperglycemia), cancer (e.g.,
cancer, malignant neoplasm), and prog-
nosis (e.g., mortality, survival, recur-
rence) and was limited to English
language human studies. We also
searched references of included articles.
Study selection
Our overall search targeted articles that
met the following three criteria: 1) evalu-
ated any prognostic outcome by glycemic
status, 2) evaluated a cancer population,
and 3) contained original data. The cur-
rent review further required articles to
evaluateshort-termpostoperativemortal-
ity after initial cancer surgery, including
30-day and hospital mortality. To be in-
cluded in our meta-analysis, articles had
to meet either of the following two crite-
ria: 1) report a risk estimate (e.g., hazard
ratio[HR],relativerisk[RR],oroddsratio
[OR])relatingpreexistingdiabetestosub-
sequent death and an estimate of preci-
sionsuchasastandarderroror95%CIor
2) report rates of short-term mortality in
patientswithandwithoutdiabetesaswell
as the prevalence of diabetes in the study
population.
Data extraction and quality
assessment
Titles, abstracts, and articles were re-
viewed independently by two authors.
Disagreements were settled by consensus
or a third review for adjudication. Ab-
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characteristics, health outcomes (speciﬁ-
cally short-term postoperative mortality
for this report), adjustment variables, and
study quality. Quality was assessed using
elements of the STrengthening the Re-
portingofOBservationalstudiesinEpide-
miology (STROBE) checklist for cohort
studies that we considered important for
qualityinthesestudies(6).Tojudgequal-
ity, we abstracted information on popula-
tion source; method of diabetes and
outcomeascertainment;whetherdiabetes
was the primary exposure variable or one
of a group of prognostic variables; and
adjustment for confounders.
Data synthesis and analyses
Articles reporting unadjusted or adjusted
risk estimates (OR, RR, or HR) and conﬁ-
dence intervals (CIs) or standard errors
(SEs) were included in the meta-analysis.
An unadjusted OR was calculated for
manuscripts reporting rates of mortality,
study sample size, and prevalence of dia-
betes. SE of the OR was calculated using
the delta method. If an article only re-
ported multiple risk estimates by sub-
group, these estimates were input
separately into our meta-analysis. We at-
tempted to contact four authors for addi-
tional unreported information necessary
for inclusion in the meta-analysis, but
none were able to furnish the required
information.Thesefourarticleswereonly
included in the systematic review.
The results of the overall systematic
review are summarized qualitatively. Ad-
ditionally, cancer sites with at least three
studies meeting inclusion criteria are
discussed in more detail. For the
meta-analysis, potential sources of heter-
ogeneity between studies were assessed
using Cochran’s Q and I
2 statistics (7).
Due to substantial between-study het-
erogeneity, we calculated a pooled
OR including all estimates using the
DerSimonian-Laird method for a random-
effects model, which weights individual
studies by the inverse of the variance (8).
Publication bias was evaluated using
Begg’sfunnelplotandtheEggerplot.Sev-
eral sensitivity analyses were conducted.
First, we excluded unadjusted risk esti-
mates.Wealsocalculatedseparatepooled
estimates for population-based and clin-
ic-based cohorts, as well as studies evalu-
ating diabetes as the primary exposure or
among prognostic factors. Next, we per-
formed the Duval and Tweedie nonpara-
metric trim and ﬁll procedure to further
assess the potential effect of publication
bias. This method considers the possibil-
ity of hypothetical missing studies, im-
putestheirORs,andrecalculatesapooled
estimate (9). Finally, we evaluated the in-
ﬂuence of each study on the overall esti-
mate by calculating a random-effects
pooled OR, omitting each estimate one at
a time. We repeated the analysis of inﬂu-
ence among studies with adjusted esti-
mates. All analyses were conducted using
STATA 10 (College Station, TX).
RESULTS
Search results
Our literature search yielded 8,828 arti-
cles, of which 20 were eligible for inclu-
sion in the present systematic review of
the risk of preexisting diabetes on short-
termpostoperativemortalityincancerpa-
tients after initial surgical treatment.
Descriptive data and main results from
these studies are presented according to
cancer site (Table 1). Of these, 15 met
additional inclusion criteria for our meta-
analysis (Fig. 1).
Nineteen articles included in our sys-
tematic review evaluated postoperative,
30-day,orhospitalmortalityincohortsof
patients who had undergone cancer sur-
gery; one article evaluated a composite
outcome of hospital mortality or morbid-
ity. Publication year ranged from 1983 to
2009. Studies evaluated the effect of pre-
existing diabetes in patients with colon or
colorectal (n  5) (10–14), esophageal
and/or gastroesophageal junction (n  5)
(15–19), liver (n  2) (20,21), lung (n 
4) (22–25), pancreatic (n  2) (26,27),
stomach(n1)(28),andprostatecancer
(n  1) (29). The studies were conducted
in Europe (n  8), the U.S. (n  7), and
Asia(n5).Samplesizesrangedfrom70
to32,621withamedianof427.Theprev-
alence of diabetes, where reported,
ranged from 1 to 42% with a median of
10%. Crude postoperative mortality rates
rangedfrom0.73to53.5%withamedian
of 6.5%.
Quality varied across studies (see sup-
plemental Table, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1721/DC1). Five
studiesusedpopulation-basedcohorts,and
theother15usedclinic-basedcohorts.Two
studies ascertained diabetes by a blood test,
and the remainder used medical records
(n18).Afewstudiesuseddeathregistries
(n  3) to ascertain vital status, but most
studies used medical records or study fol-
low-up (n  17). Only three studies
focused speciﬁcally on diabetes; the re-
maining 17 studies investigated diabetes as
one potential prognostic variable among
many. Twelve studies reported unadjusted
percentages or risk estimates of preexisting
diabetes on short-term mortality, whereas
the other eight reported adjusted estimates.
Systematic review
Of the 10 studies that reported simple
percentages comparing cancer patients
with and without preexisting diabetes,
fourreportedthatdiabeteswasassociated
with signiﬁcantly higher short-term mor-
tality, four reported nonsigniﬁcant differ-
ences, and two did not report a statistical
comparison. Neither of the two studies
reporting unadjusted estimates from re-
gressionmodelsfoundasigniﬁcantdiffer-
ence. Of the 10 adjusted estimates (eight
studies) from regression models, ﬁve in-
dicated signiﬁcantly increased risk of
postoperativemortality,onereportedsig-
niﬁcantly increased risk of postoperative
mortality or morbidity, and four found
nonsigniﬁcant associations. No studies
reported that diabetes was associated
with signiﬁcantly decreased short-term
postoperative mortality.
Oursearchyieldedatleastthreestud-
iesofcolon/colorectalcancer,esophageal/
gastrointestinal junction cancer, and lung
cancer. Results from these studies are
summarized below. We did not perform
meta-analysisbycancersitebecauseofin-
sufﬁcient number of studies with adjust-
ment and the high degree of heter-
ogeneity.
Five studies evaluated the risk of dia-
betes on postoperative mortality in colon
(10,12) or colorectal (11,13,14) cancer.
Koperna et al. (10) and Tsugawa et al.
(12) both evaluated small clinical popu-
lations (n  99 and n  71, respectively)
of patients 70 years of age undergoing
emergency surgery for colon cancer. Both
studies reported high rates of postopera-
tive mortality (50.5 and 53.5%, respec-
tively) and found a signiﬁcant survival
advantageforpatientswithoutdiabetesin
a simple comparison of postoperative
mortality rates. Little et al. (11) and Jul-
lumstrøetal.(14)evaluatedlargerclinical
cohorts (n  727 and n  1,194, respec-
tively) of colorectal cancer patients and
reported unadjusted rates of 30-day mor-
tality in patients with and without diabe-
tes. Little et al. (11) found that patients
withdiabeteshadasigniﬁcantlyincreased
risk of 30-day mortality (8.2 vs. 2.4%,
P  0.02) in a cohort of patients with
colorectal cancer that was metastatic to
the liver and who underwent hepatic re-
Cancer patients with preexisting diabetes
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 4, APRIL 2010 935section. Jullumstrø et al. (14) found no
signiﬁcant difference in 30-day mortality
betweenpatientswithandwithoutdiabe-
tes (6 vs. 5%, P  0.61) in a cohort of
colorectal cancer patients. Finally, Davila
et al. (13) evaluated the risk of 30-day
mortality in 32,621 colorectal cancer pa-
tients with and without diabetes from the
Veteran’s Affairs Database. After adjust-
ment for confounders, they observed a
signiﬁcant increase in risk for patients
with diabetes (HR 1.19 [95% CI
1.04–1.36]).
Five studies reported the risk of dia-
betes on postoperative mortality in pa-
tients undergoing treatment for cancer of
the esophagus or gastroesophageal junc-
tion (15–19). Karl et al. (17) and Abu-
nasra et al. (18) reported rates of 30-day
mortalityinclinicalpopulationswithcan-
cer of the gastrointestinal junction or gas-
trointestinal junction/esophagus,
respectively.Bothreportedhigherratesof
30-day mortality among patients with di-
abetes (13 vs. 1%, P not reported; and 11
vs. 4%, P  0.030, respectively). Bartels
et al. (16) reported that, after adjustment
for confounders, diabetes was not associ-
ated with 30-day mortality in a clinical
cohort of 432 patients undergoing cura-
tive esophagectomy (OR not reported;
P  0.05). Zhang et al. (15) found that a
four-level ordinal deﬁnition of diabetes
based on an oral glucose tolerance test
signiﬁcantly predicted hospital complica-
tion mortality (OR 1.19 per level; P 
0.024)inanadjustedpredictionmodelin
a clinical cohort of 100 esophageal cancer
patients. Finally, Wright et al. (19) found
thatconcomitantdiabetesin2,315cancer
patientsundergoingesophagectomyfrom
the Society of Thoracic Surgeons’ Data-
base was associated with an adjusted OR
of 1.19 (P  0.009) for the composite
outcome of hospital morbidity or
mortality.
Four studies investigated the effect of
diabetesonpostoperativemortalityinpa-
tients with lung cancer (22–25). In a co-
hort of 12,439 patients from California
hospitals, Romano and Mark (22) found
that diabetes was associated with an in-
creased risk of 30-day mortality in lung
cancer patients undergoing lesser resec-
tions (OR 1.5 [95% CI 1.1–2.2]) but not
in patients undergoing complete pneu-
monectomy (1.4 [0.7–2.9]). Duque et al.
(24) found a nonsigniﬁcant association
between diabetes and 30-day mortality
(1.83 [0.68–4.91]) in 605 lung cancer
patients from 16 hospitals in Spain. Au et
al. (23) and Dominguez-Ventura et al.
(25) studied older clinical populations,
and each found nonsigniﬁcant associa-
tions between diabetes and 30-day
mortality.
Meta-analysis
Of the 20 studies with 22 risk estimates
included in our systematic review, we ex-
cluded six estimates for the purpose of
meta-analysis: four estimates for lack of
sufﬁcient information (16,23,26,28) and
two for use of different exposure or out-
come deﬁnitions from other included
studies (15,19). Thus, we included in the
meta-analysis15studiesreporting16risk
estimates.
Figure 2 displays the results of the
meta-analysis of the 16 estimates in order
of magnitude. Compared with their non-
diabetic counterparts, cancer patients
with preexisting diabetes had greater
odds of mortality after surgery (OR 1.85
[1.40–2.45]). Although the studies in-
cluded in the meta-analysis spanned dif-
ferentcontinentsandcancersites,therisk
estimate was above the null in 15 of 16
estimates and signiﬁcantly above the null
in9of16estimates.Thisrelationshipwas
attenuated, but still statistically signiﬁ-
cant, after excluding unadjusted esti-
mates (1.51 [1.13–2.02]; Table 2). Age
(n4),sex(n4),andothercomorbid-
ites (n  4) were adjustment variables in
the majority of these studies (see Table 1
for a complete list in each study). The
pooled risk estimates were lower in pop-
ulation-based cohorts (1.51 [1.13–2.02])
than clinic-based cohorts (2.28 [1.46–
3.58]),likelybecausetheformerreported
adjusted risk estimates and the latter did
not. Estimates were similar in the three
studies where diabetes was the primary
exposure variable (1.69 [0.73–3.88]) and
the 12 studies where diabetes was one
among several prognostic variables (1.88
[1.38–2.55]). We observed evidence of
publicationbiasaccordingtotheBeggtest
(P  0.096) and the Egger plot (P 
0.001) (supplemental Fig. A). There was
also signiﬁcant evidence of heterogeneity
(Q  30.31 on 15 d.f., P  0.011; and
I
2  50.5%, P  0.011). To reduce the
inﬂuence of publication bias, we used the
trimandﬁllmethodforbothadjustedand
unadjustedestimates.Thismethodadded
ﬁve estimates to balance the funnel plot
(supplemental Fig. B), and the adjusted
risk estimate was attenuated but re-
mained signiﬁcant (OR 1.52 [1.13–
2.04]).
Figure 1—Flowchart of study selection.
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pooled estimate revealed that the risk of
postoperative mortality among patients
with diabetes remained signiﬁcant with
the omission of each study in turn (data
not shown). When the analysis of inﬂu-
ence was repeated in the ﬁve studies that
reported adjusted estimates, the pooled
risk estimate ranged from OR 1.32 (95%
CI 1.10–1.59) to 1.73 (1.23–2.43) and
remained statistically signiﬁcant with the
omission of each study.
CONCLUSIONS — We found that
preexisting diabetes conferred a 50% in-
creased risk of mortality in newly diag-
nosed cancer patients after surgery. This
additional risk was present across a range
of cancers and a range of surgical cancer
treatments. It was not explained by con-
founding factors, publication bias, or un-
due inﬂuence by a single study. Strengths
ofourstudyincludeacomprehensivesys-
tematic review of the literature by a mul-
tidisciplinary team including specialists
in cancer, diabetes, and epidemiologic
methods.Weusedabroadsearchstrategy
to capture all relevant information.
Limitations of the literature and of
our systematic review and meta-analysis
deservecomment.First,thepublishedlit-
erature showed great heterogeneity in
population demographics and in assess-
ment of confounders. Despite the use of
appropriate meta-analytic techniques
with random-effect models, we were un-
able to account fully for these differences.
However, we continued to observe a sig-
niﬁcant association when limiting our
pooled estimate to adjusted models, most
of which were high-quality studies per-
formed in large cohorts. Second, we
found no studies evaluating the effect of
diabetes on postoperative mortality in
women with breast or endometrial can-
cer. Thus, we are uncertain whether our
ﬁndings apply to women with these
cancers.
All articles included in the present
systematic review were based on surgical
cohorts. A notable gap in the literature is
data regarding diabetes’ effect on short-
term survival in cancer patients who do
not undergo surgery. This gap may be es-
pecially important because diabetes is
known to inﬂuence treatment decisions
and might steer some patients toward
nonsurgical treatment (2).
Previous studies of preexisting diabe-
tes and the risk of postoperative or in-
hospital mortality related to noncancer
surgery have shown mixed results
(30,31). However, there are two main
pathways through which preexisting dia-
betes might speciﬁcally inﬂuence postop-
erative mortality risk after cancer surgery.
The ﬁrst pathway is via sepsis and other
serious infection. Diabetes is a well-
established risk factor for infection and
for infection-related mortality in the gen-
eral population. Diabetes complications
like peripheral arterial disease and blad-
derdysfunctionrepresentchronicpredis-
posingfactors.Inadditiontothesefactors
is perioperative hyperglycemia, which
predicts in-hospital infection likely re-
Figure 2—Meta-analysis and pooled ORs of postoperative mortality in 15 studies comparing cancer patients with and without preexisting diabetes.
p, pneumonectomies; lr, lesser resections.
Table 2—Pooled ORs of postoperative morality in cancer patients with and without preexist-
ing diabetes
Type of estimate Number of estimates Pooled OR (95% CI)
All estimates 16 1.85 (1.40–2.45)
Only adjusted estimates 5 1.51 (1.13–2.02)
Adjustment for publication bias by
trim and ﬁll
21 1.52 (1.13–2.04)
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tion(32).Inapopulationofbonemarrow
transplantationrecipients,whoarehighly
susceptible to infection, Derr et al. (33)
reported positive associations between
preneutropenia glycemia and risks of any
infection and bloodstream infection.
The second pathway to postoperative
mortalityriskisviamyocardialinfarction.
Diabetes is a chronic risk factor for ath-
erosclerosis in multiple vascular beds, in-
cluding the coronary arteries, and is a
strong predictor of myocardial infarction
and cardiovascular disease death in the
general population (34). Superimposed
on long-standing atherosclerosis are
short-term effects of hyperglycemia on
platelet function and thrombotic ten-
dency (35). Perioperative renal failure
(e.g., diabetes-related contrast nephropa-
thy), in addition to diabetes-related
chronic kidney disease (36), may also ag-
gravate cardiovascular risk.
Theseobservationsraiseatherapeutic
question: might improvements in periop-
erative diabetes care reduce the risk of
postoperative mortality after cancer sur-
gery? There are no clinical trials that ad-
dress this question directly. Trials and
quasi-experimental studies of improved
glycemic control in the setting of noncan-
cer surgery have been generally favorable
(37,38). However, randomized con-
trolled trials of intensive insulin therapy
to achieve glycemic control in surgical in-
tensive care units have yielded mixed re-
sults (39,40).
The main implication of our study is
thatoncologists,surgeons,andcancerpa-
tients should be aware of the excess post-
operative mortality risk related to
diabetes when considering treatment op-
tions. Whether improvements in periop-
erative diabetes care can reduce this
excess risk is uncertain. Future research
should investigate physiologic pathways
to mortality risk and determine whether
improvements in perioperative diabetes
care can reduce postoperative mortality.
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